Literature DB >> 18478032

Neuregulin 1 in neural development, synaptic plasticity and schizophrenia.

Lin Mei1, Wen-Cheng Xiong.   

Abstract

Schizophrenia is a highly debilitating mental disorder that affects approximately 1% of the general population, yet it continues to be poorly understood. Recent studies have identified variations in several genes that are associated with this disorder in diverse populations, including those that encode neuregulin 1 (NRG1) and its receptor ErbB4. The past few years have witnessed exciting progress in our knowledge of NRG1 and ErbB4 functions and the biological basis of the increased risk for schizophrenia that is potentially conferred by polymorphisms in the two genes. An improved understanding of the mechanisms by which altered function of NRG1 and ErbB4 contributes to schizophrenia might eventually lead to the development of more effective therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18478032      PMCID: PMC2682371          DOI: 10.1038/nrn2392

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  211 in total

1.  Polymorphisms within 5' end of the Neuregulin 1 gene are genetically associated with schizophrenia in the Chinese population.

Authors:  J X Tang; W Y Chen; G He; J Zhou; N F Gu; G Y Feng; L He
Journal:  Mol Psychiatry       Date:  2004-01       Impact factor: 15.992

Review 2.  The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia.

Authors:  Hans O Kalkman
Journal:  Pharmacol Ther       Date:  2006-01-23       Impact factor: 12.310

3.  Heregulin-stimulated acetylcholine receptor gene expression in muscle: requirement for MAP kinase and evidence for a parallel inhibitory pathway independent of electrical activity.

Authors:  N Altiok; S Altiok; J P Changeux
Journal:  EMBO J       Date:  1997-02-17       Impact factor: 11.598

4.  Neuregulin blocks synaptic strengthening after epileptiform activity in the rat hippocampus.

Authors:  Sloka S Iyengar; David D Mott
Journal:  Brain Res       Date:  2008-02-29       Impact factor: 3.252

Review 5.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

6.  Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival.

Authors:  Bing-Sheng Li; Wu Ma; Howard Jaffe; Yali Zheng; Satoru Takahashi; Lei Zhang; Ashok B Kulkarni; Harish C Pant
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

7.  NRG1 and synaptic function in the CNS.

Authors:  Gerald D Fischbach
Journal:  Neuron       Date:  2007-05-24       Impact factor: 17.173

8.  Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse.

Authors:  Mari S Golub; Stacey L Germann; K C Kent Lloyd
Journal:  Behav Brain Res       Date:  2004-08-12       Impact factor: 3.332

9.  Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia.

Authors:  Nadine Norton; Valentina Moskvina; Derek W Morris; Nicholas J Bray; Stanley Zammit; Nigel M Williams; Hywel J Williams; Anna C Preece; Sarah Dwyer; Jennifer C Wilkinson; Gillian Spurlock; George Kirov; Paul Buckland; John L Waddington; Michael Gill; Aiden P Corvin; Michael J Owen; Michael C O'Donovan
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-01-05       Impact factor: 3.568

10.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia.

Authors:  Cathryn M Lewis; Douglas F Levinson; Lesley H Wise; Lynn E DeLisi; Richard E Straub; Iiris Hovatta; Nigel M Williams; Sibylle G Schwab; Ann E Pulver; Stephen V Faraone; Linda M Brzustowicz; Charles A Kaufmann; David L Garver; Hugh M D Gurling; Eva Lindholm; Hilary Coon; Hans W Moises; William Byerley; Sarah H Shaw; Andrea Mesen; Robin Sherrington; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael C O'Donovan; Michael J Owen; Dieter B Wildenauer; Wolfgang Maier; Gerald Nestadt; Jean-Louis Blouin; Stylianos E Antonarakis; Bryan J Mowry; Jeremy M Silverman; Raymond R Crowe; C Robert Cloninger; Ming T Tsuang; Dolores Malaspina; Jill M Harkavy-Friedman; Dragan M Svrakic; Anne S Bassett; Jennifer Holcomb; Gursharan Kalsi; Andrew McQuillin; Jon Brynjolfson; Thordur Sigmundsson; Hannes Petursson; Elena Jazin; Tomas Zoëga; Tomas Helgason
Journal:  Am J Hum Genet       Date:  2003-06-11       Impact factor: 11.025

View more
  438 in total

1.  Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.

Authors:  Kristin K Nicodemus; Amanda J Law; Eugenia Radulescu; Augustin Luna; Bhaskar Kolachana; Radhakrishna Vakkalanka; Dan Rujescu; Ina Giegling; Richard E Straub; Kate McGee; Bert Gold; Michael Dean; Pierandrea Muglia; Joseph H Callicott; Hao-Yang Tan; Daniel R Weinberger
Journal:  Arch Gen Psychiatry       Date:  2010-10

2.  Disrupted activity in the hippocampal-accumbens circuit of type III neuregulin 1 mutant mice.

Authors:  Malcolm W Nason; Avishek Adhikari; Marjan Bozinoski; Joshua A Gordon; Lorna W Role
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

3.  Resequencing and association analysis of PTPRA, a possible susceptibility gene for schizophrenia and autism spectrum disorders.

Authors:  Jingrui Xing; Chenyao Wang; Hiroki Kimura; Yuto Takasaki; Shohko Kunimoto; Akira Yoshimi; Yukako Nakamura; Takayoshi Koide; Masahiro Banno; Itaru Kushima; Yota Uno; Takashi Okada; Branko Aleksic; Masashi Ikeda; Nakao Iwata; Norio Ozaki
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

Review 4.  The contribution of GABAergic dysfunction to neurodevelopmental disorders.

Authors:  Kartik Ramamoorthi; Yingxi Lin
Journal:  Trends Mol Med       Date:  2011-04-21       Impact factor: 11.951

5.  Neuregulin directly decreases voltage-gated sodium current in hippocampal ErbB4-expressing interneurons.

Authors:  Megan J Janssen; Elias Leiva-Salcedo; Andres Buonanno
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

Review 6.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

7.  Disruption of hippocampal neuregulin 1-ErbB4 signaling contributes to the hippocampus-dependent cognitive impairment induced by isoflurane in aged mice.

Authors:  Xiao-Min Li; Fan Su; Mu-Huo Ji; Guang-Fen Zhang; Li-Li Qiu; Min Jia; Jun Gao; Zhongcong Xie; Jian-Jun Yang
Journal:  Anesthesiology       Date:  2014-07       Impact factor: 7.892

8.  Perinatal phencyclidine administration decreases the density of cortical interneurons and increases the expression of neuregulin-1.

Authors:  Nevena V Radonjić; Igor Jakovcevski; Vladimir Bumbaširević; Nataša D Petronijević
Journal:  Psychopharmacology (Berl)       Date:  2013-02-05       Impact factor: 4.530

9.  Genetics and smoking.

Authors:  Anu Loukola; Jenni Hällfors; Tellervo Korhonen; Jaakko Kaprio
Journal:  Curr Addict Rep       Date:  2014-03-01

10.  The involvement of Type II Neuregulin-1 in rat visuospatial learning and memory.

Authors:  Adam R Taylor; Sara B Taylor; James I Koenig
Journal:  Neurosci Lett       Date:  2012-10-23       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.